Arthur Groy

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 590 citations · Full text

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill et al. · Nature Cancer · 2021 · 251 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +9

Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction

Aidan G. Gilmartin, Thomas Faitg, Mark C. Richter et al. · Nature Chemical Biology · 2014 · 204 citations

Proteinlipid Interaction, Protein Function, Signal Transduction +8

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia

Ujunwa Cynthia Okoye-Okafor, Boris Bartholdy, Jessy Cartier et al. · Nature Chemical Biology · 2015 · 174 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +8

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

Peter Sabbatini, Susan Korenchuk, Jason L. Rowand et al. · Molecular Cancer Therapeutics · 2009 · 98 citations · Full text

Antitumor Activity, Immunology, Glucose Homeostasis +16